CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid…
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May…
TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) (OTCQX:VHIBF) is pleased to announce…
CINCINNATI, May 02, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based…
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend…
GUANGZHOU, China, May 02, 2024 (GLOBE NEWSWIRE) -- Guangzhou Bio-gene Technologies, a biotechnology company engaged in the discovery, development, and…
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)…